Supporting Data doc 13KB

Efficacy of Agents Used in the Prevention of Migraine in Children

This study aimed to evaluate the effectiveness of different approaches for preventing chronic migraine (CM) treatment. Materials and Methods: 578 patients with CM who applied to Diyarbakır children's hospital between 2021-2022 were included in the study. Results: The patients were divided into six groups according to the preventive oral medicine they were given. Cyproheptadine group one (n=204/0,25mg/kg/day , max 8 mg/day), Topiramate group two ( n=226/ 2 mg per kilogram per day max 100mg/day), valproic acid group three (n=16/ 10mg-15mg/kg7day,max 500 mg/night) , Lamtrijine group four( n=29/2mg/kg/day, max 100 75mg/day), amyıtrptiline group five ( n= 28/ 10mg/day to 30 mg/day after ECG control) and vitamin + co-factor group six (n=81) . The primary outcome was a relative reduction of 50% or more in the number of headache days. There were no significant between-group differences in the primary outcome, which occurred in, 51% of the patients in the cyproheptadine group, 57% of those in the topiramate group, 59% of those in the valproic acid group, 55% of those in the lamotrigine group, 52% of the patients in the amitriptyline group, and 57% of those in the vitamin /co-factor group. Topiramate was the most effective agent regarding effectiveness. It also improved the quality of life more rapidly and significantly and was better tolerated. Conclusion: . Topiramate is effective as a preventative treatment and has few side effects.